<SUBMISSION>
<ACCESSION-NUMBER>0001144204-05-019468
<TYPE>6-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20050621
<FILING-DATE>20050621
<DATE-OF-FILING-DATE-CHANGE>20050621
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>pSivida LTD
<CIK>0001314102
<ASSIGNED-SIC>3826
<IRS-NUMBER>000000000
<STATE-OF-INCORPORATION>C3
<FISCAL-YEAR-END>0630
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>6-K
<ACT>34
<FILE-NUMBER>000-51122
<FILM-NUMBER>05906950
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
<PHONE>61 8 9226 5099
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v020445_6k.htm
<TEXT>
<html>
  <head>
    <title></title></head>
  <body bgcolor="#ffffff">
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><a name="return"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
        AND EXCHANGE COMMISSION</strong></font></a></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
        D.C. 20549</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>FORM
        6-K</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">REPORT
        OF
        FOREIGN ISSUER<br></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
        to Rule 13a-16 or 15d-16 of<br></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
        Securities Exchange Act of 1934</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>For
        the month of June 2005</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Commission
        File Number 000-5112</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>pSivida
        Limited<br></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
        of registrant&#8217;s name into English) </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level
        12
        BGC Centre<br></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28
        The
        Esplanade<br></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Perth
        WA
        6000<br></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
        of principal executive offices)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Indicate
        by check mark whether the registrant files or will file annual reports under
        cover Form&#160;20-F or Form&#160;40-F).</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
        20-F
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form
        40-F </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark if the registrant is submitting the Form 6-K in paper as permitted
        by Regulation S-T Rule 101(b)(1):</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark if the registrant is submitting the Form 6-K in paper as permitted
        by Regulation S-T Rule 101(b)(7):</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark whether the registrant by furnishing the information contained
        in
        this Form is also thereby furnishing the information to the Commission pursuant
        to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
        </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No
        </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
        "Yes"
        is marked, indicate below the file number assigned to the registrant in
        connection with Rule&#160;12g3-2(b): 82- ___. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURE
        </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
        to the requirements of the Securities Exchange Act of 1934, the registrant,
        pSivida Limited, has duly caused this report to be signed on its behalf by
        the
        undersigned, thereunto duly authorized. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
        <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

            <tr valign="top" bgcolor="#ffffff">
              <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                Limited</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:
                June 21, 2005</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:&#160;&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/s/&#160;Aaron
                Finlay</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td colspan="2"><font style="FONT-FAMILY: Times New Roman" size="1">&#160;</font></td>
              <td align="left">
                <hr style="COLOR: #000000" align="left" noshade size="2" width="80%">
              </td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Aaron
                Finlay<br></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Chief
                Financial Officer and Company
                Secretary</em></font></font></td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>EXHIBIT
        INDEX</u></em></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td align="left" valign="top" width="15%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>EXHIBIT
                  99.1:</strong></font></div>
              </td>
              <td align="left" valign="top" width="62%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BrachySil&#8482;
                  Cancer Therapy Achieves Primary Endpoint in Phase IIa Clinical
                  Trials</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-2-</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v020445_ex99-1.htm
<TEXT>
<HTML>
  <HEAD>
         <TITLE></TITLE>
  </HEAD>
  <BODY BGCOLOR="#ffffff">
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="left">&#160;</DIV>
         <DIV ALIGN="center">
                <TABLE BGCOLOR="#ffffff" BORDER="0" CELLPADDING="0"
                 CELLSPACING="0" WIDTH="100%">
                  <TR BGCOLOR="#ffffff">
                         <TD WIDTH="50%">&#160;</TD>
                         <TD WIDTH="50%"><IMG SRC="logo.jpg" ALIGN="RIGHT" WIDTH="256"
                                HEIGHT="72" BORDER="0"> </TD>
                  </TR>
                  <TR BGCOLOR="#ffffff">
                         <TD WIDTH="50%"><STRONG><FONT SIZE="2">ASX/MEDIA
                                RELEASE</FONT></STRONG></TD>
                         <TD WIDTH="50%">
                                <DIV STYLE="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
                                 ALIGN="right">&#160;<STRONG><FONT SIZE="2">21<FONT
                                  STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><SUP>st</SUP></FONT><FONT
                                  STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> June
                                  2005</FONT></FONT></STRONG></DIV> </TD>
                  </TR>
                </TABLE> </DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="left"><FONT ID="TAB2"
                STYLE="COLOR: black; LETTER-SPACING: 161.1pt">&#160;</FONT><FONT ID="TAB2"
                STYLE="COLOR: black; LETTER-SPACING: 0.9pt">&#160;</FONT><FONT ID="TAB2"
                STYLE="COLOR: black; LETTER-SPACING: 27pt">&#160;</FONT><FONT ID="TAB2"
                STYLE="COLOR: black; LETTER-SPACING: 27pt">&#160;</FONT><FONT ID="TAB2"
                STYLE="COLOR: black; LETTER-SPACING: 27pt">&#160;</FONT><FONT ID="TAB2"
                STYLE="COLOR: black; LETTER-SPACING: 27pt">&#160;</FONT><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>&#160;</STRONG></FONT><FONT
                ID="TAB2" STYLE="COLOR: black; LETTER-SPACING: 27pt">&#160;</FONT></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="center"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><STRONG>BrachySil&#153;
                Cancer Therapy Achieves Primary Endpoint </STRONG></FONT></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="center"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><STRONG>in
                Phase IIa Clinical Trials</STRONG></FONT></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="center"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG><EM>Final
                Report Confirms BrachySil&#153; Safe and Well
                Tolerated</EM></STRONG></FONT></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify">
                <DIV>
                  <HR STYLE="COLOR: #000000" ALIGN="center" NOSHADE="NOSHADE" SIZE="2"
                        WIDTH="100%"> </DIV><BR></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Global
                nanotechnology company pSivida Limited (</FONT><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>ASX:PSD,
                NASDAQ:PSDV, XETRA:PSI) </STRONG></FONT><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">and the
                Singapore General Hospital (&#147;SGH&#148;), are very pleased to announce key
                findings from the final report on its Phase IIa clinical trials with
                BrachySil&#153; as a potential new brachytherapy treatment for inoperable
                primary liver cancer. </FONT></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><BR></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
                report confirms that the primary endpoint of the trial was achieved in its key
                first indication in that BrachySil&#153; (32-P BioSilicon&#153;) was found to
                be both safe and well tolerated. The trial was conducted at the SGH on eight
                patients with advanced liver cancer who were evaluated after three and six
                months following treatment. </FONT></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><BR></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Among
                other key findings of the trial was the finding that</FONT><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</FONT><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BrachySil&#153;
                also reduced significantly the size of tumors treated as determined by CT
                scanning. These combined results pave the way for a multi-centre Phase IIb
                dose-profiling study for BrachySil&#153; in this indication, which is scheduled
                to begin later in 2005. This study is expected to provide data to support the
                registration of BrachySil&#153; as an approved treatment for liver cancer.
                </FONT></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><BR></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Gavin
                Rezos, Managing Director of pSivida, said, &#147;This report confirms the
                excellent results for BrachySil&#153; that we previously announced at the
                12-week interim study time point, and will provide not only a robust foundation
                for future clinical development and regulatory filing, but also a springboard
                for our ongoing licensing activities with partners looking to enhance their own
                portfolios of specialist cancer therapies.&#148;</FONT></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><BR></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dr
                Pierce Chow, Senior Consultant, Hepatobiliary and General Surgery at Singapore
                General Hospital, said, &#147;From the perspective of patients suffering with
                advanced cancer of this kind, BrachySil&#153; promises to offer the possibility
                of an effective, safe and relatively pain-free treatment, which can potentially
                improve both the duration and quality of life. We, at the SGH, are very
                encouraged by the promising data seen to date with BrachySil&#153; and are
                optimistic that subsequent clinical trials will continue to show positive
                results in this and other serious cancer indications.&#148;</FONT></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><BR></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BrachySil&#153;
                is a micron-sized nanostructured silicon particle in which radioactive
                32-phosphorus (32-P) is immobilized. It is administered as a liquid suspension
                through a fine-gauge needle directly into tumors. The procedure takes place
                under local anaesthetic and without the need for shielded rooms or robotic
                injectors, and patients can be discharged the next day. </FONT></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><BR></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>Key
                Findings</STRONG></FONT></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><BR></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
                final report of the Phase IIa clinical trial has confirmed </FONT><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>four
                </STRONG></FONT><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">key
                findings:</FONT></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><BR></DIV>
         <TABLE CELLPADDING="0" CELLSPACING="0" ID="list" WIDTH="100%">
                <TR VALIGN="top" STYLE="LINE-HEIGHT: 1.25">
                  <TD ALIGN="right" STYLE="WIDTH: 18pt"><FONT
                         STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif"><EM>&middot;&#160;&#160;</EM></FONT></TD>

                  <TD>
                         <DIV STYLE="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
                          ALIGN="justify"><FONT
                                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG><EM>Safety
                                - No product-related adverse events</EM></STRONG></FONT></DIV>
                         <DIV STYLE="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
                          ALIGN="justify"><FONT SIZE="2">BrachySil&#153; was found to be well tolerated
                                by all eight patients in the trial group. No significant product-related
                                adverse events were reported either immediately following implantation or
                                during the six month follow-up period. Adverse events tended to be mild and
                                transient. </FONT></DIV> </TD>
                </TR>
         </TABLE>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify">&#160;</DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify">&#160;</DIV>
         <DIV ID="PGBRK"
          STYLE="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                <DIV ID="FTR">
                  <DIV ID="GLFTR" STYLE="WIDTH: 100%" ALIGN="left">&#160;</DIV> </DIV>
                <DIV ID="PN" STYLE="PAGE-BREAK-AFTER: always">
                  <DIV STYLE="WIDTH: 100%; TEXT-ALIGN: center">&#160;</DIV>
                  <DIV STYLE="WIDTH: 100%; TEXT-ALIGN: center">
                         <HR STYLE="COLOR: black" NOSHADE="NOSHADE" SIZE="2"> </DIV> </DIV>
                <DIV ID="HDR">
                  <DIV ID="GLHDR" STYLE="WIDTH: 100%" ALIGN="right">&#160;</DIV> </DIV>
                </DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><BR></DIV>
         <TABLE CELLPADDING="0" CELLSPACING="0" ID="list" WIDTH="100%">
                <TR VALIGN="top" STYLE="LINE-HEIGHT: 1.25">
                  <TD ALIGN="right" STYLE="WIDTH: 18pt"><FONT
                         STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif"><EM>&middot;&#160;&#160;</EM></FONT></TD>

                  <TD>
                         <DIV STYLE="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
                          ALIGN="justify"><FONT
                                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG><EM>Efficacy
                                - Treated tumors demonstrate significant tumor
                                regression</EM></STRONG></FONT></DIV>
                         <DIV STYLE="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
                          ALIGN="justify"><FONT SIZE="2">Implanting BrachySil&#153; directly into tumors
                                results in significant tumoricidal activity. Although the primary objective of
                                the study was to determine the safety profile of BrachySil&#153;, CT scan
                                analysis of tumors at the time of treatment and three and six months later
                                demonstrates significant tumor regression in targeted lesions with a maximum
                                regression of 100% in some small tumors from the dose used in the
                                trial.</FONT></DIV> </TD>
                </TR>
         </TABLE>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</FONT></DIV>

         <TABLE CELLPADDING="0" CELLSPACING="0" ID="list" WIDTH="100%">
                <TR VALIGN="top" STYLE="LINE-HEIGHT: 1.25">
                  <TD ALIGN="right" STYLE="WIDTH: 18pt"><FONT
                         STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif"><EM>&middot;&#160;&#160;</EM></FONT></TD>

                  <TD>
                         <DIV STYLE="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
                          ALIGN="justify"><FONT
                                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG><EM>Specificity
                                - Retention of radioactivity in the tumor</EM></STRONG></FONT></DIV>
                         <DIV STYLE="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
                          ALIGN="justify"><FONT SIZE="2">A key finding is that BrachySil&#153;
                                microparticles remain in the tumor with no or insignificant detectable
                                radioactive leakage. This observation is a very significant outcome for the
                                trial. Unlike other liver brachytherapy approaches that involve delivery via
                                the hepatic artery which, in some cases, results in radioactivity becoming
                                associated with healthy tissue, BrachySil&#153; is administered directly into
                                tumors restricting radioactivity to the tumor itself.</FONT></DIV> </TD>
                </TR>
         </TABLE>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify">&#160;</DIV>
         <TABLE CELLPADDING="0" CELLSPACING="0" ID="list" WIDTH="100%">
                <TR VALIGN="top" STYLE="LINE-HEIGHT: 1.25">
                  <TD ALIGN="right" STYLE="WIDTH: 18pt"><FONT
                         STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif"><EM>&middot;&#160;&#160;</EM></FONT></TD>

                  <TD>
                         <DIV STYLE="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
                          ALIGN="justify"><FONT
                                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG><EM>Ease
                                Of Application - Practical and rapid treatment of tumors with ultrasound and CT
                                guidance</EM></STRONG></FONT></DIV>
                         <DIV STYLE="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
                          ALIGN="justify"><FONT SIZE="2">The procedure has been shown to be
                                straightforward and accurate for the treatment of tumors in a routine and
                                conventional clinical setting. From a market perspective, this demonstration is
                                in line with the Company&#146;s strategy to develop a simple procedure for the
                                nuclear medicine physician and interventional radiologist to selectively treat
                                specific tumors. </FONT></DIV> </TD>
                </TR>
         </TABLE>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify">&#160;</DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>Next
                Steps</STRONG></FONT></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><BR></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
                mentioned above, pSivida is planning to initiate a multi-centre Phase IIb
                dose-profiling study for BrachySil&#153; as a treatment for advanced liver
                cancer in the second half of 2005. </FONT></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><BR></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
                Company plans to pursue a &#145;device-based&#146; regulatory strategy, with
                BrachySil&#153; filings scheduled in 2007 initially as a treatment for liver
                cancer and thereafter for the treatment for other cancers involving solid
                tumors.</FONT></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><BR></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                has already started a development programme for BrachySil&#153; in a second key
                cancer indication - pancreatic cancer - and plans to commence Phase IIa
                clinical trials before the end of 2005 to evaluate and safety and tolerability
                of the treatment. The trial will also monitor the efficacy of the treatment
                based on CT measurements of tumor regression as a foundation for subsequent
                Phase IIb dose-profiling studies. </FONT></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><BR></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Finally,
                pSivida will employ a multi-injector/implanter device that will be clinically
                evaluated in all subsequent trials using BrachySil&#153; as a means of ensuring
                effective distribution of the implanted dose from a single entry point. This
                device will, for the first time, enable physicians to treat larger tumors and
                could represent a significant advantage of BrachySil&#153; over existing
                brachytherapies. The Company is currently seeking development and marketing
                partners for BrachySil&#153; in the major territories.</FONT><FONT ID="TAB2"
                STYLE="COLOR: black; LETTER-SPACING: 27pt">&#160;</FONT></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><BR></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>Notes
                on BrachySil&#153; and competitive advantages in brachytherapy
                </STRONG></FONT></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><BR></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BrachySil&#153;
                (32-P-BioSilicon&#153;) is being manufactured to regulatory guidelines by
                supply chain contract partners including Atomising Systems Ltd and High Force
                Ltd in the UK and Auriga Medical in Germany. Importantly the manufacturing
                process has already been scaled up successfully to supply materials for
                clinical trial programmes and early product launch.</FONT></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><BR>&#160;</DIV>
         <DIV ID="PGBRK"
          STYLE="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                <DIV ID="FTR">
                  <DIV ID="GLFTR" STYLE="WIDTH: 100%" ALIGN="left">&#160;</DIV> </DIV>
                <DIV ID="PN" STYLE="PAGE-BREAK-AFTER: always">
                  <DIV STYLE="WIDTH: 100%; TEXT-ALIGN: center">&#160;</DIV>
                  <DIV STYLE="WIDTH: 100%; TEXT-ALIGN: center">
                         <HR STYLE="COLOR: black" NOSHADE="NOSHADE" SIZE="2"> </DIV> </DIV>
                <DIV ID="HDR">
                  <DIV ID="GLHDR" STYLE="WIDTH: 100%" ALIGN="right">&#160;</DIV> </DIV>
                </DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify">&#160;</DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Brachytherapy
                treatment utilising BrachySil&#153; includes the following potential
                advantages:</FONT></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify">&#160;</DIV>
         <TABLE CELLPADDING="0" CELLSPACING="0" ID="list" WIDTH="100%">
                <TR VALIGN="top" STYLE="LINE-HEIGHT: 1.25">
                  <TD ALIGN="right" STYLE="WIDTH: 36pt"><FONT
                         STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&middot;&#160;&#160;</FONT></TD>

                  <TD>
                         <DIV STYLE="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
                          ALIGN="justify"><FONT
                                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>Short
                                range </STRONG></FONT><FONT
                                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 32-P
                                isotope has a short active range resulting in controlled exposure to
                                radioactivity and less damage to healthy tissue.</FONT></DIV> </TD>
                </TR>
         </TABLE>
         <TABLE CELLPADDING="0" CELLSPACING="0" ID="list" WIDTH="100%">
                <TR VALIGN="top" STYLE="LINE-HEIGHT: 1.25">
                  <TD ALIGN="right" STYLE="WIDTH: 36pt"><FONT
                         STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&middot;&#160;&#160;</FONT></TD>

                  <TD>
                         <DIV STYLE="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
                          ALIGN="justify"><FONT
                                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>Immobilization
                                </STRONG></FONT><FONT
                                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 32-P
                                device is immobilized in the tumor, significantly reducing risk of leakage or
                                systemic side effects.</FONT></DIV> </TD>
                </TR>
         </TABLE>
         <TABLE CELLPADDING="0" CELLSPACING="0" ID="list" WIDTH="100%">
                <TR VALIGN="top" STYLE="LINE-HEIGHT: 1.25">
                  <TD ALIGN="right" STYLE="WIDTH: 36pt"><FONT
                         STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&middot;&#160;&#160;</FONT></TD>

                  <TD>
                         <DIV STYLE="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
                          ALIGN="justify"><FONT
                                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>Ease
                                of application </STRONG></FONT><FONT
                                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-
                                BrachySil&#153; is delivered under local anaesthetic and patients can be
                                discharged the next day.</FONT></DIV> </TD>
                </TR>
         </TABLE>
         <TABLE CELLPADDING="0" CELLSPACING="0" ID="list" WIDTH="100%">
                <TR VALIGN="top" STYLE="LINE-HEIGHT: 1.25">
                  <TD ALIGN="right" STYLE="WIDTH: 36pt"><FONT
                         STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&middot;&#160;&#160;</FONT></TD>

                  <TD>
                         <DIV STYLE="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
                          ALIGN="justify"><FONT
                                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>Direct
                                delivery </STRONG></FONT><FONT
                                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-
                                BrachySil&#153; is delivered via fine-gauge needle, minimizing side effects and
                                tissue trauma without the need for shielded rooms or robotic injectors allowing
                                treatment in hospitals without the need for investment in specialised
                                facilities.</FONT></DIV> </TD>
                </TR>
         </TABLE>
         <TABLE CELLPADDING="0" CELLSPACING="0" ID="list" WIDTH="100%">
                <TR VALIGN="top" STYLE="LINE-HEIGHT: 1.25">
                  <TD ALIGN="right" STYLE="WIDTH: 36pt"><FONT
                         STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&middot;&#160;&#160;</FONT></TD>

                  <TD>
                         <DIV STYLE="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
                          ALIGN="justify"><FONT
                                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>Range
                                of tumors </STRONG></FONT><FONT
                                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-
                                fine-gauge needle delivery allows potential application to many solid tumors,
                                unlike current brachytherapy products.</FONT></DIV> </TD>
                </TR>
         </TABLE>
         <TABLE CELLPADDING="0" CELLSPACING="0" ID="list" WIDTH="100%">
                <TR VALIGN="top" STYLE="LINE-HEIGHT: 1.25">
                  <TD ALIGN="right" STYLE="WIDTH: 36pt"><FONT
                         STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&middot;&#160;&#160;</FONT></TD>

                  <TD>
                         <DIV STYLE="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
                          ALIGN="justify"><FONT
                                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>Distribution
                                </STRONG></FONT><FONT
                                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 32-P
                                half-life of 14 days allows convenient distribution to hospitals and
                                application in the patient.</FONT></DIV> </TD>
                </TR>
         </TABLE>
         <TABLE CELLPADDING="0" CELLSPACING="0" ID="list" WIDTH="100%">
                <TR VALIGN="top" STYLE="LINE-HEIGHT: 1.25">
                  <TD ALIGN="right" STYLE="WIDTH: 36pt"><FONT
                         STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&middot;&#160;&#160;</FONT></TD>

                  <TD>
                         <DIV STYLE="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
                          ALIGN="justify"><FONT
                                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>Manufacture
                                </STRONG></FONT><FONT
                                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-
                                BioSilicon&#153; is &#147;radiation hard&#148; allowing ease of manufacture of
                                BrachySil&#153; from phosphorus-doped silicon used in the electronics industry
                                without the need to build costly manufacturing facilities.</FONT></DIV> </TD>
                </TR>
         </TABLE>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify">&#160;</DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify">&#160;</DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="center"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>-ENDS-</STRONG></FONT><BR></DIV>

         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="left"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>For
                further information, please contact:</STRONG></FONT></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="left"><BR>
                <DIV ALIGN="left">
                  <TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
                         <TR>
                                <TD ALIGN="left" VALIGN="top" WIDTH="50%"
                                 STYLE="BORDER-BOTTOM: medium none">
                                  <DIV
                                        STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
                                        ALIGN="left"><FONT
                                         STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>pSivida
                                         Limited</STRONG></FONT><FONT
                                         STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</FONT></DIV>

                                  <DIV
                                        STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
                                        ALIGN="left"><FONT
                                         STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Gavin
                                         Rezos, Managing Director</FONT></DIV>
                                  <DIV
                                        STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
                                        ALIGN="left"><FONT
                                         STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Joshua
                                         Mann, CFA, Investor Relations</FONT></DIV> </TD>
                                <TD ALIGN="left" VALIGN="top" WIDTH="50%"
                                 STYLE="BORDER-BOTTOM: medium none">
                                  <DIV
                                        STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
                                        ALIGN="left"><FONT
                                         STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel: +
                                         61 (8) 9226 5099</FONT></DIV> </TD>
                         </TR>
                         <TR>
                                <TD ALIGN="left" VALIGN="top" WIDTH="50%"
                                 STYLE="BORDER-BOTTOM: medium none">&#160;</TD>
                                <TD ALIGN="left" VALIGN="top" WIDTH="50%"
                                 STYLE="BORDER-BOTTOM: medium none">&#160;</TD>
                         </TR>
                         <TR>
                                <TD ALIGN="left" VALIGN="top" WIDTH="50%"
                                 STYLE="BORDER-BOTTOM: medium none">
                                  <DIV
                                        STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
                                        ALIGN="left"><FONT
                                         STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>Singapore
                                         General Hospital</STRONG></FONT></DIV>
                                  <DIV
                                        STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
                                        ALIGN="left"><FONT
                                         STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ms
                                         Angela Ng,</FONT></DIV>
                                  <DIV
                                        STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
                                        ALIGN="left"><FONT
                                         STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Assistant
                                         Manager, Corporate Communications </FONT></DIV> </TD>
                                <TD ALIGN="left" VALIGN="top" WIDTH="50%"
                                 STYLE="BORDER-BOTTOM: medium none">
                                  <DIV
                                        STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
                                        ALIGN="left"><FONT
                                         STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel: +
                                         65 6321 4325 </FONT></DIV> </TD>
                         </TR>
                         <TR>
                                <TD ALIGN="left" VALIGN="top" WIDTH="50%"
                                 STYLE="BORDER-BOTTOM: medium none">&#160;</TD>
                                <TD ALIGN="left" VALIGN="top" WIDTH="50%"
                                 STYLE="BORDER-BOTTOM: medium none">&#160;</TD>
                         </TR>
                         <TR>
                                <TD ALIGN="justify" VALIGN="top" WIDTH="50%"
                                 STYLE="BORDER-BOTTOM: medium none">
                                  <DIV
                                        STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
                                        ALIGN="justify"><FONT
                                         STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>US
                                         Public Relations</STRONG></FONT></DIV>
                                  <DIV
                                        STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
                                        ALIGN="justify"><FONT
                                         STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Beverly
                                         Jedynak, Martin E. Janis &amp; Co. </FONT></DIV> </TD>
                                <TD ALIGN="justify" VALIGN="top" WIDTH="50%"
                                 STYLE="BORDER-BOTTOM: medium none">
                                  <DIV
                                        STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
                                        ALIGN="justify"><FONT
                                         STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel: +1
                                         (312) 943 1100</FONT></DIV> </TD>
                         </TR>
                         <TR>
                                <TD ALIGN="justify" VALIGN="top" WIDTH="50%"
                                 STYLE="BORDER-BOTTOM: medium none">&#160;</TD>
                                <TD ALIGN="justify" VALIGN="top" WIDTH="50%"
                                 STYLE="BORDER-BOTTOM: medium none">&#160;</TD>
                         </TR>
                         <TR>
                                <TD ALIGN="justify" VALIGN="top" WIDTH="50%"
                                 STYLE="BORDER-BOTTOM: medium none">
                                  <DIV
                                        STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
                                        ALIGN="justify"><FONT
                                         STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>UK
                                         &amp; Europe Public Relations</STRONG></FONT></DIV>
                                  <DIV
                                        STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
                                        ALIGN="justify"><FONT
                                         STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mark
                                         Swallow, Ph.D, Citigate Dewe Rogerson</FONT></DIV> </TD>
                                <TD ALIGN="justify" VALIGN="top" WIDTH="50%"
                                 STYLE="BORDER-BOTTOM: medium none">
                                  <DIV
                                        STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
                                        ALIGN="justify"><FONT
                                         STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel: +44
                                         (0)20 7638 9571</FONT></DIV> </TD>
                         </TR>
                  </TABLE> </DIV> </DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="left"><BR>&#160;</DIV>
         <DIV ID="PGBRK"
          STYLE="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                <DIV ID="FTR">
                  <DIV ID="GLFTR" STYLE="WIDTH: 100%" ALIGN="left">&#160;</DIV> </DIV>
                <DIV ID="PN" STYLE="PAGE-BREAK-AFTER: always">
                  <DIV STYLE="WIDTH: 100%; TEXT-ALIGN: center">&#160;</DIV>
                  <DIV STYLE="WIDTH: 100%; TEXT-ALIGN: center">
                         <HR STYLE="COLOR: black" NOSHADE="NOSHADE" SIZE="2"> </DIV> </DIV>
                <DIV ID="HDR">
                  <DIV ID="GLHDR" STYLE="WIDTH: 100%" ALIGN="right">&#160;</DIV> </DIV>
                </DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="left">&#160;</DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>NOTES
                TO EDITORS:</STRONG></FONT></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><BR></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="left"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>pSivida
                Limited</STRONG></FONT></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                is a global nanotechnology company committed to the biomedical sector and the
                development of products in healthcare. The company&#146;s focus is the
                development and commercialisation of a modified form of silicon (porosified or
                nano-structured silicon) known as BioSilicon&#153;. As a new and exciting
                biocompatible material, BioSilicon&#153; offers multiple potential applications
                across the high growth healthcare sector, including controlled release drug
                delivery, targeted cancer therapies (including brachytherapy and localized
                chemotherapy), tissue engineering and orthopedics. Potential diagnostics
                applications are being developed through its subsidiary AION Diagnostics
                Limited. </FONT></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><BR></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                owns the intellectual property rights to BioSilicon&#153; for use in or on
                humans and animals. The IP portfolio consists of 26 patent families, 30 granted
                patents and over 80 patent applications. The core patent, which recognises
                BioSilicon&#153; as a biomaterial was granted in the UK in 2000 and in the US
                in 2001. </FONT></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><BR></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                is listed on NASDAQ (</FONT><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>PSDV</STRONG></FONT><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">), the
                Australian Stock Exchange (</FONT><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>PSD</STRONG></FONT><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">) and in
                Germany on the Frankfurt Stock Exchange on the XETRA system (</FONT><FONT STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>German</STRONG></FONT><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</FONT><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>Symbol:
                PSI. Securities Code (WKN) 358705</STRONG></FONT><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">).
                pSivida&#146;s shares also trade in the United Kingdom on the OFEX
                International Market Service (IMS) under the ticker symbol </FONT><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>PSD</STRONG></FONT><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</FONT></DIV>

         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><BR></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
                Company&#146;s strategic partner and largest shareholder is the QinetiQ group,
                the largest science and technology company in Europe. QinetiQ is the former UK
                government Defence Evaluation Research Agency and was instrumental in
                discovering BioSilicon&#153;. pSivida enjoys a strong relationship with QinetiQ
                having access to its cutting edge research and development facilities. For more
                information on QinetiQ visit </FONT><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><U>www.qinetiq.com</U></FONT><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</FONT></DIV>

         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><BR></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For more
                information visit </FONT><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><U>www.psivida.com</U></FONT></DIV>

         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><BR></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>Singapore
                General Hospital</STRONG></FONT></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Singapore
                General Hospital (SGH) is Singapore&#146;s oldest and largest tertiary acute
                care hospital and national referral centre. It offers a comprehensive range of
                clinical specialties and support services for the South-East Asia region.
                Annually, 70,000 patients are admitted to the hospital and 600,000 attend its
                specialist outpatient clinics. SGH also recognizes research and education as
                essential pillars of healthcare. Drawing upon its wealth of resources (clinical
                expertise, modern research facilities, and patient data and specimens), the
                Hospital&#146;s researchers are pursuing, in an integrated and holistic manner,
                the full range of &#145;molecules-to-communities&#146; studies. Extensive
                teaching and educational services are also offered.</FONT></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><BR></DIV>
         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify"><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For more
                information visit </FONT><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><U>www.sgh.com.sg</U></FONT></DIV>

         <DIV
          STYLE="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
          ALIGN="justify">&#160;</DIV>
         <DIV><BR></DIV>
         <DIV><FONT
                STYLE="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">This
                document contains forward-looking statements that involve risks and
                uncertainties. Although we believe that the expectations reflected in such
                forward-looking statements are reasonable at this time, we can give no
                assurance that such expectations will prove to be correct. Given these
                uncertainties, readers are cautioned not to place undue reliance on such
                forward-looking statements. Actual results could differ materially from those
                anticipated in these forward-looking statements due to many important factors
                including: our failure to develop applications for BioSiliconTM due to
                regulatory, scientific or other issues. Other reasons are contained in
                cautionary statements in the Registration Statement on Form 20-F filed with the
                U.S. Securities and Exchange Commission, including, without limitation, under
                Item&#160;3.D, "Risk Factors" therein. We do not undertake to update any oral
                or written forward-looking statements that may be made by or on behalf of
                pSivida.</FONT></DIV>
         <DIV>&#160;</DIV>
         <DIV>&#160;</DIV>
         <DIV ID="PGBRK"
          STYLE="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                <DIV ID="FTR">
                  <DIV ID="GLFTR" STYLE="WIDTH: 100%" ALIGN="left">&#160;</DIV> </DIV>
                <DIV ID="PN">
                  <DIV STYLE="WIDTH: 100%; TEXT-ALIGN: center">&#160;</DIV>
                  <DIV STYLE="WIDTH: 100%; TEXT-ALIGN: center">
                         <HR STYLE="COLOR: black" NOSHADE="NOSHADE" SIZE="2"> </DIV> </DIV>
                <DIV ID="HDR">
                  <DIV ID="GLHDR" STYLE="WIDTH: 100%" ALIGN="right">&#160;</DIV> </DIV>
                </DIV> </BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````4```_^X`#D%D
M;V)E`&3``````?_;`(0``@("`@("`@("`@,"`@(#!`,"`@,$!00$!`0$!08%
M!04%!04&!@<'"`<'!@D)"@H)"0P,#`P,#`P,#`P,#`P,#`$#`P,%!`4)!@8)
M#0L)"PT/#@X.#@\/#`P,#`P/#PP,#`P,#`\,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,_\``$0@`2`$``P$1``(1`0,1`?_$`+X``0`"`P`#`0``````
M```````'"`4&"0(#!`H!`0`!!0$!`0`````````````$`@,%!@<(`0D0``$#
M`P,"`P4#"04%"0````$"`P0`!081$@<A"#$3%$%1(C()87$5@9%"4B.T%C9V
ML<1U-SBA8K(D='*"DJ(S<[.4)1$``0,"`P,(!@<%"0$!`````0`"`Q$$(1(%
M,4$&46%Q@2(R$P>1H;'!,Q3PX4)28G(TT?&R(Q6"DJ+"<X/#-3:3)?_:``P#
M`0`"$0,1`#\`[^41*(E$2B)1$HB41*(J_P#*_<OQ9Q',9L%VN<C(\XG:)M?'
MV/,FXW>0XKY$>0V=&MWL\Q2=?9K5QD3G="Q-_K-O9G*XESSL:W%WU=:C!K(>
M\_DD^MQW$\0X)QUT;X2<I6[>+VM)^4N1XQ#+1(\4+`4*KI&WE)4(3:K<FK&,
MB;^+M.]6`Z"*K!<*<T\SL]PN7=O',3]DRJ?:+,F\V_+;!%5$0A)0PX$O-DZ;
M5I?`^4%*AIJH*!'U\;<@<%:TW4KH7S[2XHX@5#@.C;Z>3:KV5'6T)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(O4J0PA?EK>;2X>H;*@%?
MFJTZ>-KLI<`>2HJOM"O;5U?$HB41:QF&76K"+#,R*\M3Y$.'H/36R%(N$MU9
MUVH:CQ6W'%$Z>[0>T@54UA<:!6+FX;`PO=6G,"3Z`J9N7WN8[EG'8N+0)7;?
MQ`^M3;V4W-L_Q;<V0=#Z:-JGTH5^L2"/$+5\M7J,CVXGU+7?%O\`4\&`PQ<I
M^(>@;OIB=BG[B/@#BG@Z,Y_"]K0[D,\;KQF=W=$J[S5J^93DESJD*/4I;"4_
M9KUJ-/>-'?<!TD!9?3M'@LA_+;5V]QQ<>O\`8I`Y$S['.,,+R#.\JEB)9,>B
MJD2"--[J_!IAI/Z3CJR$('M)JMK2XT"DW=TRUB=+(:`#Z#K5;^UCCK*TS<[[
M@.3H)MG(G-$AN2S85@[K19&0/10U:]0LH"2H$:@)0#\6ZKLSA@T;`L/H=G)5
M]W,*22XT^ZW</IR#>KBU86PI1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$
M2B)1$HB41*(HKY!PNPW!J7DLR*AZ?':;;6J1.5"8#:5;=5.`*"2-WNZURWC[
M@S3;QC]2F8'2M#0<TIA9E!I4NHX`BO)CL4VUN'MHP'#HJHRX\S"Y6#)F<6N%
MS;NUHN+B68CK4@2D,..#]GY;PTU!.B5#W]=!7-/+[B^ZTC5VZ5<3":"0AK2'
MB4,<[N97\FQKAACB`,:S+NW;)'G`H1S44T93A/\`$TIF6,@N=G6PQY*6H3NQ
MM7Q%6Y2?:>OOKLO%'!7]<F;+\U-"6MRTC=1IQ)J1O./+L"Q\%SX0IE!Z53Z3
M>;]&DR8QOL]9CNK:*_4NC78HIUTW>W2O(%UK&I03/B^:E.5Q%<[MQIRK/MC8
M17*/0ISX[PZ7D%F@9%,RR\MNJDJ*8C4A7E[67--%;B2=VWK7<?+S@Z;6+"+4
M9[ZX#B\]D/.6C'4H:UK6F*QMW<"-Y8&A;=ROFTG%K7&A6MP-7:[;PV_XEEE&
MF]:1^L20!^4^RMO\UN-9=`LV0VII/-6AWL8-KA^(UHWK.T*/8VPE=5VP*.L)
MPRS9&N0O(Y,>ZR&6?52KC'NY?>&XC:EQI(^``:ZDJ/6N?\$<%66N.=_4'-FD
M`SN>RX,C\2*-<P#LTQJ2XFOJE7-RZ(=G`=%%GIG'LGE;-;-E.<-*;X_P24)7
M'V$.:[;A<&QHF\W-L^/E^$5D_+U<7\2@E/IIM(VY6K4GVINYA)+\-IJUO*?O
MN_RCK.VBL!5"RJ41*(E$7BM:&T+<<4$(;!4M9Z``=22:I>\,:7.-`,2456\H
MYHO<N:_&QCR[?;T+*&):FPX^\`=`K18*4@^P::UY>XH\Y]0N+AT6F4CB!H'4
M#GOY^U4-!W#+7G6:ATY@%7XE8!/)7)-G>9=GRWMKGQ)CSXB4(<'MT^!"OS&M
M?;YD\5Z;(U]P]U#L;+&`'?X6G^Z0KWR<#Q@/058;`<[B9K`=46DP[K"T$^$#
MJ-%?*XV3U*3I^0]/O]#<!\=0<3VQ=3).RF=G3L<W\)](.!W$XFZMC">8KRY)
MA7VX8P['QP2#<S)94D1G/*<V!7Q?%N3TT^VOOF/9:C=Z0Z/3L_C9VD9'974K
MCC5OM2S<QLE7[%KG%%JRZV"^_P`5)F)+QC^A]6_YWR^9OV_&O3Q&M:YY4Z5K
MEB+G^JB3M9,F=^?9GS4[3J;6U5V^?&[+DIOV*8*Z^H"41*(J+=\6&\X9C8./
MF.$FKZY/@W*:Y?Q8[C^'K#*V$!KS5>>QO&X'0:G2I%NYH)S+5N*+:\GC8+7-
M4$URFG)SA;MV9XQRMB?$DRU\Q-W9O+%Y#-?93>9OKY'HUM1PUH[YKWP[DKT&
M[IUZ53.6EW9V*3PW!<PVI;<USYCM-32@YRK9U96P+'7>0[$M-TE,*"7XT1]U
ME1&H"T-J4DZ'QZBOH5$A+6DCD7&WMM[Q^?N1><>/<)RS*H4_';_.?8ND1JUP
MV%K0B*\ZD!QML*3\2`>AJ=+;L:TD+FVB<2WMU>1Q2.!:XXX#D/,NT=0%TQ*(
ME$2B)1$HBPF1H=<L=S0PEY;Q9/EICLM2'200?@:>_9J/V*K"\1,>_3Y@P.+L
MN&5K9'?V62=AQYG8*Y":/%54S+4385\L$R2U<([H4A3:Y\*+!/[)X*^!,4E*
M@->I/6O)_%C+BUU&UFE;,UU10RQ10=UP/9$)+32N)./4L[`0YC@*=1)]JR_(
M/<?.5RO8.#N&K$<VS=%SB*Y'N82?08_:@\V9:GG#M2IXM*(`UT22!\2R$5[1
MCB%,SMBY_>:P[YAMM;-S/J,QW,;7'KI]*X*+[MM_%;IM^7UDC;]WF*K\\M6_
M63?G=_$5TIG='0K<</\`\AVS_P!Z3_\`,JO7'D__`.;A_-)_&5@=0^,>I1=S
M!NEYYC\)M+CJDQ8Z0TPA+CA4N0LZ(0LA*E$`:`]#[:YAYOEUQQ):0-#B<C,&
M@.=5TCNZUW9)V4!P._!3+#"%QYS[%*V!QYR7KHY-9N+22AM*$W"WPH6[4J)V
M&*25?:%>%=5X#@N6R3.F;,W!H'BPPP5Q/=\'%W/FP&%%"NB"!2G42?:I*KI"
MAI1%37O3YTSG@7!L3R'!!;C<+S?OPZ9^)1U2&_)]*\]\*4N-Z'<@==:D6\8>
M2"M:XFU6;3H6/BI4NIB*[B54W$N^WG/-L(;L&#<<#/>879$M^ZS+;;9"[?;+
M:DI3&48[2U%QQ1W'52TI'3YCT%YULUIJ30+!6W%5Y<0Y8H\\V-:`T:-V'IYN
ME:-QK]0CF/&\]C6?F>+"NF.&?Z#)8XMPMUQM?[3RW'$I;VZEDZE3:T:D`C4&
MJGVK2VK5#LN,+J*?)<@%M:'"A;^[D*[*Y$AVY8O>D6U7G/3K:^(2FS\Y<:.S
M:?\`>UZ5J?$UO-<:5=10_$=$\-Z2T@#K74H'#.TG94*EN'76%8LFL]TN<<O0
MX3^Z0V!JI.J2D+"?:4$[M/LKQ9P=JEOI.L6]U=-S1QN[0IB,"`ZG*PG-3F6Q
MW##)&6MVE6_NL''N1<<>C1YK,N))`5&GLZ+4PZ.J5`'0I4/:#ITZ5Z^U2RTS
MC+2W11R-?&[NO;0ECAL--H(WM-#2H*P#'/MWU(H5\&'\<6;#9"YL*3*ESWF2
MP\^\L!!05!1`;2`/$#QUJ!P?Y<V'#4AFA>]\CFY27$4I4'N@`;AMJJKB[=,*
M&E%[^1LBN.+XT[=;7Y7JT2&6AYR=Z=JU:'H"*O>8G$-UH6DNN[7+G#VCM"HH
M=N%0OEI$V63*[8M=XKS6]9@+X;QZ?_\`/,<1_(;*/_5\S=KJHZ_**UWRLXUO
M^)!<_.9/Y>3+E&7O9JUQ/W0KU];,AIEWU7/;NE[N^?N#>8K_`(59_P"'GL<,
M:+<\:=EVYQ;RHLEOJE:P^D**'4.(U`]E=IA@8]M5S'7N(;W3[LQ-RY<"*C<>
MOEJNEMDSJU7/C:U\DO/(;LTS'&LBDO(.J4,*B"4YI_V4ZU$+:.HMUBNFOMQ-
M]DMS=5*KE]V^=YW/O,W->(X(XSC[..W>:_)N_DVY8?:MD9"WW`'"^0%%*0@*
M(\2.E3)8&,;5:-H_$M[?7C8J-RDXX;ACR]2LUWM=P.?\!6'`;C@0MAD9)<9D
M6Y?B494E/EL,H<1L"7&]#JHZU9MX@\FJS?$^KS:=&QT5*DFM17D6Y]G7,>8\
MX\43,RSCT'XRQD$RVH_#F#'9\AAIA:-4*6L[M7#J=:IGC#'4"D\.:E+?VQEE
MI7,1AAN'[5%_>;W=7;@A^RX1@,.%+SF]Q#<9UQGH+S%NAE9;:(92I.]UU2%Z
M;CHD)U(.HJNW@SXG8H/$O$3M.RQQ`%Y%<=P_:56?CWO1[E&,6N&6\E<:S,ZX
MJGM/QI&:6RU+@F)N"FBXA]I/IW$(4=%!0'7IY@-77P,K0&A6%L^)-0\(R3QE
MT1J,P%*=>SZ;55#LV_U.<2:>'XG)T_\`HR:D7'PRM<X9_P"QBZ3["N^_+_*V
M,\+8#>N0,J6M4"U)2W$@,Z>?,ENG:Q&9W=-RU>T]`-5'H#6,8PO-`NNZA?QV
M,+II-@]9Y%R#N/?OW/<A7R5'XRQJ);&&DEUJR6>T.7N6VR#\S[BTN:_:H-H'
MV5.%LQNTKG3^+=0N7GP&4'(!F/7M]@6U\1_48Y$MF50;#S59X%SL,F6B'=+Q
M#BJM]PMJE*V*=<9U\MQ*#U6C:A0&NAUZ&E]J*5:I&G<93ME#+EH+:T)I0CW=
M2[.(6AQ"'&U!;;@"D+2=00>H((\0:@+I2\J(E$7HE1F)L:1#DMI>CRFU-/M*
MZI4A8*5`^'B#5BZMH[F)\,@#F/!:0=A!%"%]:2#4*GV5VNRKA,R;?<\999U>
M7;Y%H]8XB:&UEM2$ODO,E2%)(("OA5J#7E'CWA:/3OY<GRT#VU<T,;<`RMW#
M,_/'4<@<*'`E9JRNA,,S"7`[Z@CU+?.-\OXWM1O%S?MT3&<LR5YJ3EMX2P=U
MSD--)90\X\D*)^!(^$Z`'73Q)/4.$?-[3+JSCBU"3PIV-#22"6OIAF!:#2NT
MAU,>58^32!#(Y\31VC4\O6J_W!Q#L^>ZVH+;=DO+;6/`I4LD'\HKRWJ4C9+J
M5[34%[B#S$E;`P4:%8OC[/\`%<:PF'%N=RVSF')"E6]I"UNG<ZI2=`!H-0?:
M17HGR^X^T?1.'HXKJ:DK2\Y`"YV+B1NIB.4@+$W=K))*2T8*-';FUFV7R;[.
M?@1@XZAJWV2<B2]YR$IV(;VQ4%1T^8]1UKF\NILXHUM]_.Z)M7!K(9!*_.*9
M6MI"TN/*<15VS!2PSP(\HKSD4]ZL]AV.HQ^W.(5!@09<QSS)*+<EY+1`&B-?
M/4I>H'CX5Z;X/X>;H]J6F.*.1YJX1!X9^'XA<ZM-NSH6&N)?$=M)'/\`4MNK
M;582B+FC]3O_`"IX]_JS^XR*EV?>/0M(XZ_2Q_G]Q7J^F$A`XOY&<"$AQ>5(
M2MS0;BE,%DI!/CH-3I]]+SO!?.!?TTGYO<%1/OVM\.W]S>?B&PB.F=$M4N2E
M`T"GG8#7F+.GM41J?MJ3;&L:U;BQ@;J+Z;\I]07>+BM]R5QAQQ)>45O2,7L[
MKJSU)4N$R23]Y-8U_>/2NK6!+K:,G[C?8%J>;<00;Z\_=+$\BU7-XE;\90_Y
M=Y9ZE73J@GVD`C[*XMQKY0VVK2.NK%PBF-26GX;W<N&+"=Y`(/)6I6<MK\QC
M*[$>M5_>CY?Q]=$E7JK'-)^!Y!U:?2D^PC5#B?L.M<!FM]<X.O*G/!)N([CP
M.?%CV\QKSA90&*X;N(5FN..0D9E&>B36T1KY`0%R&T:['FR=/-0#X=>A'LKT
MQY<^8#>)8713`-N8Q5P'=>W9G;R8X.&XD4VX8:[M?!-1L*^7FG^1W_\`K8W_
M`!&HWG-_YYW^HSVE5:=\7J*TW@+Y<I^^'_8]6E^0>R]_VO\`D4C5/L]?N5)?
MJ>X$IR%QMR=&;)]([(QJ[K">@0\#*B$D>Y2'1U]]>E[-V)"Y3QU:5;'.-W9/
MM'O6!QSFDL_3AR&(9@:OEJ?=X^C[5:.*1-D)6D$>(_Y)Y8'V)KZ8_P"=ZU;A
MU3_\%V/:'8])K_"?4OG^F%@HDY!R3R1)8U1:8<;'K2\I/3S)2O4RMI]Z4M-`
M_8JOMX[8%1P+:5?).=PRCKQ/L'I6^?5&_E+B+_&KE^[-U19[2I?'7P8ND^Y2
M;]-G_3Y<?ZPN?[O$JB[[_4IW!7Z$_G/L"Y_?4.D.N=RM^0M1*8M@M#;`_526
M5.:?^)1-2K7N+4>,374".8>Q=F^.+-;K5V^X99H<5M%O9P.$WZ;:-B@Y;DJ<
MW)\#O*B5:^.M0'GMGI72;*-K+%C0,/#'\*X1]FO^ISB3_$Y/[C)K)7'PRN4<
M-?\`8Q=)]A7>[ESAG!N;[!`QG/XLR=9[=/3<H\:)+=B:R$-K:2I2FB"H!+BM
M`:QC)"PU"ZWJ&FPW[`R4$@&N!IBJF1>4.S[LQC9'CN'W%VYW^YR@[>K'9W57
MB=YS""A#3TEQ8:9".OP+<!!).WJ:O9))L2M?;?:7H@<R,U<3B!VCANKL'15<
M@N?.2+9R[RIFO(UFLCF/6_)G67F+6ZM#CB2S&:84M:FP$[G%-E9T]_B?&IT;
M,C*+G6JWK;R[=,UM`XC#J`7Z5^/E*7@6$+6HJ6NP6TJ4>I),5O4FL4[:5VNS
M-8&?E'L6WU2I*414"[@N7<RY-S<=KG`,S;D=P04<IY\R26+#;S\+[(<1X.E)
MT60=P)#:?C4=DF)@:,[NI:IJVH2W4OR-H>T>^[[HWCIY?1MV6?XKX2P7B7CR
MV<<6*VHG6F)J_<9,U"7')LUQ(#TIT'4!2R.@3T2-`.@K&ZE8V^HL,=S&V1A^
MRX!P]?M6?TRR9I\0CBJ*;]Y/*LO*XGP.2K=^"^G/M\AYU`/Y`O3_`&5H=UY4
M<.7!K\ME/X7O;ZLU%EVWTPWJG,YI#$Z:PV-&V)#K;8/4[4K('7[A7CJ_A;#<
MR1MV-<X#H!(6P,-0"K"\<\>XE>\5A7J\PE/R7''P\M3[C;>UMQ21J$J2!H!7
MH7RW\N]%U?1XKR[B+Y'.?7M.`[+B!@TC<%B;R[DCD+0:!319\5QRPDN6>SQ8
M3BAUD(1JYH?9YBM5:?EKLVD<+:7I)K:6[(W?>`[7]XU=ZUCY)WR=XU6P5GU:
M2B)1%S1^IW_E3Q[_`%9_<9%2[/O'H6D<=?I8_P`_N*^3Z84R(>-^1X`E-&<W
MDS<AR$%I\U+2X;*4N%&NX)*DD`Z::@U]O.\%3P*X?+R"N.;W!43[[[O`O'<U
MR$NW2$2F[<Q;;?)6V=0F1&@M)>;U'M0K5)]Q!%2+84C6K<5R-?J+\IV4'6`%
MW/Q-V[8]PMASD*$F3=K/B5JU@NA6A4S#9#B2$Z'4`'I[ZU/B:^N;&PGN+5@?
M(QI<&FM#3$[,>[6@&TKKFEQCP8F.P[+1Z@H]Q/F2Z2\BCM9*]%C6>6E36K+>
MQ#+BM"A:E**E:=-#J=!KK7`N$_.*\N=48S4G,9;O!;V6Y0QQ[KB22:?9.-!6
MIV+/3Z>T,JRM5(G*5RQM[#+BB7+BRGWDI-H0AQ*W"_J-BF]I)T'74^ZNA^:&
MHZ5)H,K9I&.<0/"`(+L]<"VF.'VCLRU&]1+)CQ**`\ZA3A=N0O-VEL@^4S"D
M*ED>&PA*0#_WB*XKY+Q2NU\.9W6QOS=&`'^+*LCJ)'A=:F;FG^1W_P#K8W_$
M:[-YS?\`GG?ZC/:5C].^+U%:;P%\N4_?#_L>K2_(/9>_[7_(I&J?9Z_<O5W;
MX"KD;M\Y'L<=OS+C;[=^-VD::J,BUJ$L)2-"=5H;4@:?K5Z/A=E>%J'$%I\S
M8R,&T"H_LX_4OSJ-9;=V\-EX.AX#'YUYCW]]CKJ9<:,[&0KW:;'C65RBM5QG
MYEXA,/V<P=U@$>]?H&[(<#3@?;G@Z7&E-7'+D.Y+<PH;3NN!"F!^2.EH5B[A
MV9Y78.&+3Y>P9RN[1Z]GJHJR_5&_E+B+_&KE^[-U>L]I6"XZ^#%TGW*3?IL_
MZ?+C_6%S_=XE47??ZE.X*_0G\Y]@5`/J'Q76NY2]N+3HF;C]H=8/O2&EM'_S
M(-2K7N+4N,134">8>SZEV,XXRBQW+MQP_)F[C'9LQP2*I^>ZXE#318@):>#B
MU$!/EK0I*M3T(J`\'.1SKHUE.QU@Q]</#'LQ7##LUZ]S?$A]]SD_N,FLE<?#
M*Y5PU_V,72?85TM^HCS3E/'6$XM@^(SGK-,Y%7-%ZO,=10^BWPTM)<CM+'5!
M>4^`I2=#M21^E4.UC#C4[EO/&.IR6L+8XS0OK4\PIAUU4)]AW:YQGGF'O<MY
M_$CYA*%U?@V;&)!W0H9B%)4[*:!T=<65:A*]4A.AT)5TN7,S@<HP6+X4T*WN
M(OF)AF-:`;A3EY>@X45-^\>5CDON(Y+5B;MO>L,94")#_"_+](A4:W1F76V_
M)^`;'$*20GP((J_!7PQ5:WQ$Z,ZB_P`.F6H&&S``>U?H;X\_D#!OZ?MG[JW6
M,?M*[!9?`C_*/8%N%4J2JE=VW.=SXIQ"V8K@K;EPY<Y.D?@^!V^.`X\RIQ26
MW)FPZ_)O"6]1H5D'P2JKT,>8U.P+`:_JCK2(1Q8RR8-'O_9SK:>VC@.V\$8(
MB`^X+KG>2J3<>0,F6HN.RYR]5%M+BM5%MHK(3K\QW+/51KY+)G/,K^BZ4VPA
MH<7NQ<>4_L'UJQE6EF$HBYDY%E\9.6SL3QRWR<TS5^4^I&+VDH6Y';\PZOSW
MU$,PV4^*G'E#IX`UXSTOR]U/B"\FE8T16X>\NFD[,8`<:Y=[Z?AP&\A9&\UV
M"TI$VLDI&#&8N_M'8P<[O05;KAO$KI_#<&?EN0QK^ZR^Z8-CM25ILT)Q+AW>
M6IQ*79:PK7]JZ`GVMMH\3Z;X"MK"TTB."PE,L37/'B$4SNS',0-S<U<O-O*Q
M4D<\DA?<TS&G9;W6^]QY2>H!3Y6XJXE$2B)1%S1^IW_E3Q[_`%9_<9%2[/O'
MH6D<=?I8_P`_N*I_VN=LEVYHXXRO,L%S^?Q]R+CE]-M@3FGGFHDF(N*TZ67E
M1BEYL[EGXTE0TZ%!\1?FER.`(J%KN@:(Z^MWR12%DC74'(10<F(^F"F#B[Z;
MN<_QK;KQR]DUD>QB#-$RZ6VUOR9<NYE"]_E+<>99"$.J^=1)41KT!.HH?=BE
M&K)6'!<WC!]RYN4&I`))=ZAM78Q*$(0EM"0A"`$I0!H`!T``J`NCJ!,MX4;N
M$QVX8S,:MYD**WK;("O)"B=26U(!*0?=H?L]U<%XM\E67L[KC39&QEQJ8W5R
M5/W7-!+1^&A`W$#!92#4<HH\5YUIL;@O*EN`2)UMC-:Z*<"W'#I[PD-C7\XK
M3+;R-UE[Z2RPM;RU<X]0RCVA2#J<8V`J>L+P:UX7#<:B*,J?*T]=<7``I>WP
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M")C*2'M#:\]:>C:NR-LMT2T6ZWVF`T&(-KC-1(3`\$,L(#:$C[DI`J`35='8
MP,:&C8!15#[Q.W#+.XNR8/;,5OEILCV+W"7+F.74OA+B)#*&TAOR&W#J"GKK
MI5^"41DU6O<1Z-)J;&-80,I.VN^G("MN[3N$<BX"XPE8/DUVMUYN+]]EW1,N
MV>:60U(:80E)\Y#:MP+1UZ:5\FD#W5"D:!IC].MS$\@G,3AT#E`Y%'?=YVBJ
M[A?P/)L5N\.P9[8&%02[<`OT<Z"5%Q+3RVDK6A32U**%!*OF4"/`BJ"?P\#L
M4+B+A[^I97L($@PQV$?4JR\6_3RY,+\2T<M\CMQN-XLL2YF#6"?,?1.6E0.B
MDNH999"R/B4$J5IX;3U%Y]TW[(Q6$T_A"X!#;B3^6#7*TG'V`=.U;3POV&\@
M<8<WXSR3*RG&G\;QZZS)B+1$5,,D1GFGVF6T>8R$ZI#B==5>SQJF2Y#F45_3
M>$YK2\;.7-RM)-!6M*'F5HN[#MH8[C<2L\6WW=JP9CBDAZ1CMSDH4N,XB2E*
M7XT@(U6$KV(4%)!*2GP()%689?#/,L[K^B#4X@`:/;L.[':"J"XA]/+N(@OR
M[3(Y/M&'XU<UA%\-HN%Q=,IH="3%0U&0[TU`#BQ4IUTP[EJ5KP??L):90UIV
MT)QZJ"O6LOF_TQLI7?)">.\YL[6+B+&;BB_*D^N4^EE*9*W/3QU-@+="E)"?
M`'3V52V[%,0KMSP/)XE87C+AWJUY]@Y5UQQ.URK'BV-62<MIV;9[5#@S'6-Q
M:4['80VLME0!VE23IJ-=*A.-35=!MXS'&UIV@`>@+,2I4>#%DS93J6(L-I;\
ME]9T2AMM)4I1/L``UKXKKG!H).P*H[W$5XRSNXQ[FF\L(N>!67`T#!9*5(4B
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M.TY#Z^?'7*CQ0ACTCS6[=(<;2?B6!H#K4BVD#"25J_%6FSWT#&0MJ0ZIQ`PH
M>4A>/8KPWR)PO@6963D:QHL5RNV0"=`81*CR@MCTK+6[='<<2/B21H3K2YD#
MR"%\X5TV>Q@>R9M"75&(.X<A*O%4=;2E$2B)1$HB41*(E$2B)1$HB41*(E$2
MB)1$HB41*(L/D-G:R&P7RP//*CLWRWR;>Z^@:J0F2TIHJ`.FI`5K7T&AJK<T
M8D8YAW@CTKF=C&'?46XLM[>$8U/QG-<8LB!"Q^[7-^(ZI$5OX&MJGE,2`$I`
MT2YNV_*"0!4HNA=B5I<-OKEJ/#86N:,`339UT/I6X)[>.[GED>3S=W!(Q/'7
MQMEXOAC?EK>;/BVXXRW%1H>OS%T?97SQ8V]T*_\`TC4[O]3/E;R,^K+_`)E8
M[B+M6X6X6<:N&*XLF=DJ`-^77A7K;B5>U3:U@(9)]OE(1K[:M/F<_:LSI^A6
MEEC&VKOO'$_5U`*Q=6EF$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$
1HB41*(E$2B)1$HB41*(O_]D_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
